457 related articles for article (PubMed ID: 30274985)
1. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).
De Sutter L; Wozniak A; Verreet J; Vanleeuw U; De Cock L; Linde N; Drechsler C; Esdar C; Sciot R; Schöffski P
Clin Cancer Res; 2023 Aug; 29(15):2859-2868. PubMed ID: 37223931
[TBL] [Abstract][Full Text] [Related]
4. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.
Gebreyohannes YK; Burton EA; Wozniak A; Matusow B; Habets G; Wellens J; Cornillie J; Lin J; Nespi M; Wu G; Zhang C; Bollag G; Debiec-Rychter M; Sciot R; Schöffski P
Clin Exp Med; 2019 May; 19(2):201-210. PubMed ID: 30523507
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
[TBL] [Abstract][Full Text] [Related]
6. Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor.
Rossi F; Liu M; Tieniber A; Etherington MS; Hanna A; Vitiello GA; Param NJ; Do K; Wang L; Antonescu CR; Zeng S; Zhang JQ; DeMatteo RP
Clin Cancer Res; 2023 Jun; 29(11):2144-2157. PubMed ID: 36971786
[TBL] [Abstract][Full Text] [Related]
7. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
8. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
[TBL] [Abstract][Full Text] [Related]
9. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.
Van Looy T; Gebreyohannes YK; Wozniak A; Cornillie J; Wellens J; Li H; Vanleeuw U; Floris G; Debiec-Rychter M; Sciot R; Schöffski P
Clin Sarcoma Res; 2014; 4():10. PubMed ID: 25132955
[TBL] [Abstract][Full Text] [Related]
10. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
George S; Jones RL; Bauer S; Kang YK; Schöffski P; Eskens F; Mir O; Cassier PA; Serrano C; Tap WD; Trent J; Rutkowski P; Patel S; Chawla SP; Meiri E; Gordon M; Zhou T; Roche M; Heinrich MC; von Mehren M
Oncologist; 2021 Apr; 26(4):e639-e649. PubMed ID: 33453089
[TBL] [Abstract][Full Text] [Related]
11. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Floris G; Debiec-Rychter M; Wozniak A; Stefan C; Normant E; Faa G; Machiels K; Vanleeuw U; Sciot R; Schöffski P
Mol Cancer Ther; 2011 Oct; 10(10):1897-908. PubMed ID: 21825009
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Garner AP; Gozgit JM; Anjum R; Vodala S; Schrock A; Zhou T; Serrano C; Eilers G; Zhu M; Ketzer J; Wardwell S; Ning Y; Song Y; Kohlmann A; Wang F; Clackson T; Heinrich MC; Fletcher JA; Bauer S; Rivera VM
Clin Cancer Res; 2014 Nov; 20(22):5745-5755. PubMed ID: 25239608
[TBL] [Abstract][Full Text] [Related]
13. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
14. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
16. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
[TBL] [Abstract][Full Text] [Related]
17. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
[TBL] [Abstract][Full Text] [Related]
20. [Advanced GIST: Which treatments in 2022?].
Mas L; Bachet JB
Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
